Sugi Predict

Sugi Predict / Targets / MAP3K1

MAP3K1

Mitogen-activated protein kinase kinase kinase 1 · Q13233 · MAP3K1 on Sugi Atlas →

16,156 patent compounds predicted against MAP3K1, 12,863 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL256391 SCHEMBL256391 0.58 3/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 2/20
Regorafenib Regorafenib (SCHEMBL432230) 1.00 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
Erlotinib Erlotinib (SCHEMBL33835) 0.89 2/20
Erlotinib Erlotinib (SCHEMBL482649) 0.89 2/20
Erlotinib Erlotinib (SCHEMBL482681) 0.89 2/20
Sorafenib Sorafenib (SCHEMBL162935) 0.81 2/20
SCHEMBL432444 SCHEMBL432444 0.81 2/20
SCHEMBL170976 SCHEMBL170976 0.80 2/20
Sorafenib Sorafenib (SCHEMBL19322) 0.80 2/20
SCHEMBL100845 SCHEMBL100845 0.80 2/20
SCHEMBL548133 SCHEMBL548133 0.79 2/20
Erlotinib Erlotinib (SCHEMBL482269) 0.77 2/20
SCHEMBL100309 SCHEMBL100309 0.77 2/20
SCHEMBL170966 SCHEMBL170966 0.74 2/20
SCHEMBL101864 SCHEMBL101864 0.74 2/20
SCHEMBL101702 SCHEMBL101702 0.71 2/20
SCHEMBL99685 SCHEMBL99685 0.71 2/20
SCHEMBL100966 SCHEMBL100966 0.70 2/20

Clinical trials — most relevant to MAP3K1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Study of ASTX029 in Subjects With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Histiocytic Disorder Follow-up Study nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MAP3K1 binder may also engage these)

ProteinNameSimilarity
Q62925 — 1.000 Q62925 →
P53349 — 1.000 P53349 →
Q5XJV7 — 0.988 Q5XJV7 →
P49140 — 0.988 P49140 →
Q8K2L8 — 0.986 Q8K2L8 →
Q9P203 — 0.986 Q9P203 →
Q9H694 — 0.985 Q9H694 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.985 landscape →
Q8WYQ5 — 0.985 Q8WYQ5 →
Q9C0A6 — 0.985 Q9C0A6 →
Q62136 — 0.984 Q62136 →
O70546 — 0.984 O70546 →
P78524 — 0.984 P78524 →
Q99PP7 — 0.984 Q99PP7 →
Q9EQM6 — 0.984 Q9EQM6 →
KAT2B Histone acetyltransferase KAT2B 0.984 landscape →
O44431 — 0.984 O44431 →
F1R7R1 — 0.983 F1R7R1 →
Q9Y4F4 — 0.983 Q9Y4F4 →
Q8CFE5 — 0.983 Q8CFE5 →
A5D794 — 0.983 A5D794 →
Q9WU40 — 0.983 Q9WU40 →
Q9WTU0 — 0.983 Q9WTU0 →
O88974 — 0.983 O88974 →
Q62315 — 0.983 Q62315 →
Q92833 — 0.983 Q92833 →
Q8TEW8 — 0.983 Q8TEW8 →
Q62415 — 0.983 Q62415 →
Q6AI12 — 0.983 Q6AI12 →
O54828 — 0.983 O54828 →